Trust Co. of Oklahoma Purchases Shares of 5,000 Novo Nordisk A/S (NYSE:NVO)
Trust Co. of Oklahoma acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,000 shares of the company’s stock, valued at approximately $214,000.
Several other large investors have also recently modified their holdings of the company. State Street Corp boosted its stake in shares of Novo Nordisk A/S by 64,406.4% in the first quarter. State Street Corp now owns 5,593,351 shares of the company’s stock worth $191,740,000 after buying an additional 5,584,680 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Novo Nordisk A/S by 17.7% in the first quarter. Renaissance Technologies LLC now owns 16,409,200 shares of the company’s stock worth $562,507,000 after buying an additional 2,463,300 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 12.9% in the second quarter. Fisher Asset Management LLC now owns 11,690,997 shares of the company’s stock worth $501,427,000 after buying an additional 1,331,992 shares in the last quarter. Karp Capital Management Corp purchased a new stake in shares of Novo Nordisk A/S during the first quarter worth about $20,651,000. Finally, Sustainable Growth Advisers LP boosted its stake in shares of Novo Nordisk A/S by 17.3% in the first quarter. Sustainable Growth Advisers LP now owns 4,068,896 shares of the company’s stock worth $139,482,000 after buying an additional 598,644 shares in the last quarter. Institutional investors own 6.40% of the company’s stock.
Shares of Novo Nordisk A/S (NYSE NVO) opened at 41.66 on Tuesday. The company has a market capitalization of $103.98 billion, a PE ratio of 17.41 and a beta of 0.63. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $50.30. The company has a 50 day moving average price of $42.86 and a 200 day moving average price of $38.45.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/08/5000-shares-in-novo-nordisk-as-nysenvo-acquired-by-trust-co-of-oklahoma-updated-updated-updated.html.
A number of equities research analysts have recently issued reports on NVO shares. Zacks Investment Research cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Wednesday, April 19th. TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a report on Tuesday, May 2nd. Finally, BidaskClub cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Five equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $53.00.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.